[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Onyema et al., 2022 - Google Patents

Endocrine abnormality in paraneoplastic syndrome

Onyema et al., 2022

View HTML
Document ID
1876599032490808348
Author
Onyema M
Drakou E
Dimitriadis G
Publication year
Publication venue
Best Practice & Research Clinical Endocrinology & Metabolism

External Links

Snippet

Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone

Similar Documents

Publication Publication Date Title
Kulke et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
Onyema et al. Endocrine abnormality in paraneoplastic syndrome
De Groot et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Dynkevich et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive
Öberg et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
Barbieri et al. Peptide receptor targeting in cancer: the somatostatin paradigm
de Herder et al. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses
Kouroumalis et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study
Alexandraki et al. The ectopic ACTH syndrome
Öberg et al. Endocrine tumours of the pancreas
Kanakis et al. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Ricci et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors
Reubi et al. In vitro detection of somatostatin receptors in human tumors
Kaltsas et al. Paraneoplastic syndromes secondary to neuroendocrine tumours
Borson-Chazot et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery
Eriksson et al. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors
Watt et al. Biology of somatostatin in breast cancer
Lasolle et al. Pasireotide: A potential therapeutic alternative for resistant prolactinoma
He et al. The browning of white adipose tissue and body weight loss in primary hyperparathyroidism
Grozinsky-Glasberg et al. The role of somatostatin analogues in the treatment of neuroendocrine tumours
Piecha et al. Multiple endocrine neoplasia type 1
Drange et al. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid
Teunissen et al. Effects of therapy with [177 Lu-DOTA 0, Tyr 3] octreotate on endocrine function
Jawiarczyk et al. Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review
Sala et al. Growth hormone-releasing hormone-producing pancreatic neuroendocrine tumor in a multiple endocrine neoplasia type 1 family with an uncommon phenotype